Abstract: Objective To investigate the effect of combined therapy of compound embryonic bovine liver extract and entecavir in patients with chronic hepatitis B. Methods Forty-eight patients with chronic hepatitis B were randomly divided into treatment group（n=24） and control group（n=24）. Patients in treatment group were treated with compound embryonic bovine liver extract plus entecavir,and those in control group were treated with entecavir alone. The treatment lasted for 48 weeks and the liver function tests,serum hepatic fibrosis indexes and the histological activity index and fibrosis before and after treatment in the two groups were examined. Results At the end of 48 weeks of the treatment,serum albumin levels in patients in treatment group（41.0±2.9 g/L）were significantly higher than that in the controls（36.2±2.2 ） g/L,P<0.01;Serum hyaluronic acids （158.0±70.3）ng/ml,laminin（83.6±29.9） ng/mland collagen type IV（90.3±41.2） ng/mlin the treatment group were significantly lower than those in the controls（170.6±71.1） ng/ml,（107.5±33.7） ng/ml and（113.5±52.4） ng/ml,respectively,P<0.05）;Histopathological examinations of the liver biopsies showed that the grades and stages of the liver injuries in treatment group were decreased significantly as compared with in control group（P<0.05）. Conclusions Combined therapy of compound embryonic bovine liver extract and entecavir are better than entecavir alone in inhibiting liver inflammation and fibrosis in patients with chronic hepatitis B.

Key words: Chronic hepatitis B, Compound embryonic bovine liver extract, Entecavir, Efficacy